AI Terminal
PROCESSING_QUERY...
HIKMA Pharmaceuticals PLC
Director's Dealing • Jun 3, 2025
4841_dirs_2025-06-03_85e34c65-3ef9-4ddc-aae8-a038507bd03f.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2553L
Hikma Pharmaceuticals Plc
03 June 2025
Hikma Pharmaceuticals PLC - EIP Vesting
LONDON, 3 June 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (Nasdaq Dubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMRs") have received shares as a result of the vesting of their conditional share awards which were granted on 30 May 2023 under the 2014 Executive Incentive Plan ("EIP").
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Said Darwazah | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Chairman | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP. All Shares were retained. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 31,679 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 31,679 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Riad Mishlawi
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Riad Mishlawi | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 36,371 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 36,371 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares sold to cover tax following the vesting of conditional awards under the EIP. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £21.38 | 13,863 | ||
| d) | Aggregated information | Price(s): £21.38 Volume(s): 13,863 Total(s): £296,418.11 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Mazen Darwazah
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Mazen Darwazah | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Vice Chairman | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP. All Shares were retained. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 36,171 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 36,171 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Khalid Nabilsi
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Khalid Nabilsi | |
| 2 | Reason for the notification | ||
| a) | Position/status | PDMR | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP. All Shares were retained. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 28,833 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 28,833 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Bassam Kanaan
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Bassam Kanaan | |
| 2 | Reason for the notification | ||
| a) | Position/status | PDMR | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 28,647 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 28,647 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares sold following the vesting of conditional awards under the EIP. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £21.38 | 28,647 | ||
| d) | Aggregated information | Price(s): £21.38 Volume(s): 28,647 Total(s): £612,529.00 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Susan Ringdal
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Susan Ringdal | |
| 2 | Reason for the notification | ||
| a) | Position/status | PDMR | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 15,925 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 15,925 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares sold to cover tax following the vesting of conditional awards under the EIP . | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £21.38 | 7,508 | ||
| d) | Aggregated information | Price(s): £ 21.38 Volume(s): 7,508 Total(s): £160,535.75 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Hussein Arkhagha
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Hussein Arkhagha | |
| 2 | Reason for the notification | ||
| a) | Position/status | PDMR | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP. All Shares were retained. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 15,983 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 15,983 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Dr Bill Larkins
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr Bill Larkins | |
| 2 | Reason for the notification | ||
| a) | Position/status | PDMR | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 8,496 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 8,496 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares sold to cover tax following the vesting of conditional awards under the EIP . | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £21.38 | 3,239 | ||
| d) | Aggregated information | Price(s): £ 21.38 Volume(s): 3,239 Total(s): £69,256.16 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Julie Hill
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Julie Hill | |
| 2 | Reason for the notification | ||
| a) | Position/status | PDMR | |
| b) | Initial notification /Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Hikma Pharmaceuticals PLC | |
| b) | LEI | 549300BNS685UXH4JI75 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares acquired from the vesting of conditional awards under the EIP. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| Nil | 5,992 | ||
| d) | Aggregated information | Price(s): nil Volume(s): 5,992 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 |
|
| b) | Nature of the transaction | Shares sold to cover tax following the vesting of conditional awards under the EIP . | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £21.38 | 2,284 | ||
| d) | Aggregated information | Price(s): £ 21.38 Volume(s): 2,284 Total(s): £48,836.39 |
|
| e) | Date of the transaction | 30 May 2025 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
Helen Middlemist
Group Company Secretary
+44 (0)20 7399 2760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBDGDLDGGDGUX
More from HIKMA Pharmaceuticals PLC
Major Shareholding Notification
2025
Nov 11
Director's Dealing
2025
Nov 11
Director's Dealing
2025
Nov 7
Earnings Release
2025
Nov 6
Director's Dealing
2025
Aug 22
Director's Dealing
2025
Aug 13
Director's Dealing
2025
Aug 8
Earnings Release
2025
Aug 7
Report Publication Announcement
2025
Jul 9
Report Publication Announcement
2025
Jul 7